Pulse Biosciences, Inc. Awards Significant Equity Grant to CTO – Potential Implications for Shareholders

HAYWARD, CA – March 27, 2026 – Pulse Biosciences, Inc. (NASDAQ: PLSE), a leading developer of novel medical technologies, has announced a major equity incentive for its Chief Technology Officer, Darrin R. Uecker. This move, approved by the company’s Compensation Committee on March 23, 2026, is designed to recognize and secure executive leadership as the company pursues development of its atrial fibrillation treatment platform – a potentially high-value market for the company and its investors.

Key Points from the Report

• Significant Equity Award: CTO Darrin R. Uecker was granted 100,000 restricted stock units (RSUs) of Pulse Biosciences’ common stock (par value \$0.001 per share).
• Vesting Period: The RSUs will vest in full on the third anniversary of the grant date, subject to the terms of the award and the company’s Amended and Restated 2017 Equity Incentive Plan.
• Purpose of the Grant: This award is in recognition of Mr. Uecker’s continued leadership in product development, specifically for the company’s ongoing efforts in the treatment of atrial fibrillation—a large and growing medical market.
• Company Details: Pulse Biosciences is incorporated in Delaware, operates under the EIN 46-5696597, and is listed on the NASDAQ under the symbol “PLSE”.
• Company Headquarters: The latest SEC document still lists the principal business address as 3957 Point Eden Way, Hayward, CA 94545, but the XBRL instance lists 601 Brickell Key Drive, Suite 1080, Miami, FL 33131, indicating a possible change or expansion of office locations.

What Shareholders Should Know

• POTENTIALLY PRICE-SENSITIVE EVENT: The grant of 100,000 RSUs—vesting over three years—signals the company’s confidence in its CTO and long-term product roadmap. Such a large grant is a strong retention tool and suggests that Pulse Biosciences expects Mr. Uecker to play a pivotal role in bringing its atrial fibrillation platform to market.
• Alignment with Shareholder Interests: The long vesting period ensures alignment of executive and shareholder interests, incentivizing the CTO to drive company value and successful product execution over the medium term.
• Product Development Focus: The disclosure explicitly ties the equity award to progress in the treatment of atrial fibrillation, a multi-billion dollar market opportunity. Investors should monitor upcoming milestones or regulatory updates regarding this platform.
• No Indication of Director or CEO Departure: There is no announcement of any director or CEO departure in this report; rather, it is focused on compensation and retention for an existing key officer.
• Governance and Plan Compliance: The RSU grant is made in accordance with the Amended and Restated 2017 Equity Incentive Plan, ensuring transparency and compliance with established shareholder-approved compensation frameworks.

Potential Share Price Impact

Equity grants of this size to critical technical leadership can be interpreted positively by the market, as they often precede or coincide with major product milestones or business development efforts. By locking in a key executive for three years, Pulse Biosciences is signaling that it expects significant progress and value creation in its product pipeline, particularly in the atrial fibrillation space.

Investors may view this as a bullish sign—especially if further announcements regarding product trials, regulatory progress, or commercial partnerships emerge in the near future.

Other Disclosures

• No written communications or soliciting materials were filed with this 8-K.
• No pre-commencement tender or issuer tender offer communications were triggered.
• Pulse Biosciences does not currently qualify as an “emerging growth company,” indicating it is subject to standard public company reporting requirements.

Conclusion

The grant of 100,000 RSUs to CTO Darrin R. Uecker is a material event for Pulse Biosciences, Inc., reflecting the company’s commitment to its executive team and its strategic focus on atrial fibrillation therapies. Investors should watch for further news on product development, clinical milestones, and commercialization efforts, as these developments could drive the company’s valuation and share price.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence or consult with a professional advisor before making any investment decisions. The information provided is based on publicly available SEC filings as of March 27, 2026, and may be subject to change.

View PULSE BIOSCIENCES, INC. Historical chart here